NeuroDerm Ltd - Product Pipeline Analysis, 2018 Update

NeuroDerm Ltd - Product Pipeline Analysis, 2018 Update

  • Products Id :- GDME7552PD
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary


NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinson's disease and central nervous system (CNS) disorders through proprietary reformulations of its existing drugs. The company's liquid formulation of levodopa/carbidopa product candidates includes ND0612L, intended for moderate Parkinson's diseases; and ND0612H, for severe Parkinson's disease. It also develops ND0701, intended for patients with severe Parkinson's disease and ND0801, a product candidate intended for the treatment of cognitive disorders associated with CNS diseases including attention deficit disorder or attention deficit hyperactivity disorder, schizophrenia, alzheimer's disease, and other diseases. NeuroDerm is headquartered in Rehovot, Israel.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.


- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company NeuroDerm Ltd

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

NeuroDerm Ltd Company Overview 5

NeuroDerm Ltd Company Snapshot 5

NeuroDerm Ltd Pipeline Products and Ongoing Clinical Trials Overview 5

NeuroDerm Ltd-Pipeline Analysis Overview 7

NeuroDerm Ltd-Key Facts 7

NeuroDerm Ltd-Major Products and Services 8

NeuroDerm Ltd Pipeline Products by Development Stage 9

NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11

NeuroDerm Ltd Pipeline Products Overview 13


CRONO ND Product Overview 13

CRONO Twin ND 14

CRONO Twin ND Product Overview 14

CRONO Twin ND Clinical Trial 15

ND0601 Dermal Patch 16

ND0601 Dermal Patch Product Overview 16

ND0611 Dermal Patch 17

ND0611 Dermal Patch Product Overview 17

ND0612H Belt Pump 18

ND0612H Belt Pump Product Overview 18

ND0612L Patch Pump 19

ND0612L Patch Pump Product Overview 19

ND0612L Patch Pump Clinical Trial 20

ND0901 21

ND0901 Product Overview 21

NeuroDerm Ltd-Key Competitors 22

NeuroDerm Ltd-Key Employees 23

NeuroDerm Ltd-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

NeuroDerm Ltd, Recent Developments 25

Aug 03, 2017: NeuroDerm Announces Second Quarter 2017 Financial Results 25

Jun 27, 2017: Results of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology 25

Jun 08, 2017: NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson's Disease and Movement Disorders 26

Jun 06, 2017: European Medicines Agency Accepts Design of NeuroDerm's ND0612 Phase III iNDiGO Efficacy Trial 28

Jun 05, 2017: NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 28

May 23, 2017: NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 30

May 11, 2017: NeuroDerm Announces First Quarter 2017 Financial Results 30

Mar 30, 2017: NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results 31

Mar 01, 2017: NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson's Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting 33

Dec 22, 2016: NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson's Disease 35

Appendix 36

Methodology 36

About GlobalData 39

Contact Us 39

Disclaimer 39

List of Figures

NeuroDerm Ltd Pipeline Products by Equipment Type 6

NeuroDerm Ltd Pipeline Products by Development Stage 9

NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11

List of Tables

NeuroDerm Ltd Pipeline Products and Ongoing Clinical Trials Overview 5

NeuroDerm Ltd Pipeline Products by Equipment Type 6

NeuroDerm Ltd Pipeline Products by Indication 6

NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 6

NeuroDerm Ltd, Key Facts 7

NeuroDerm Ltd, Major Products and Services 8

NeuroDerm Ltd Number of Pipeline Products by Development Stage 9

NeuroDerm Ltd Pipeline Products Summary by Development Stage 10

NeuroDerm Ltd Ongoing Clinical Trials by Trial Status 11

NeuroDerm Ltd Ongoing Clinical Trials Summary 12

CRONO ND-Product Status 13

CRONO ND-Product Description 13

CRONO Twin ND-Product Status 14

CRONO Twin ND-Product Description 14

CRONO Twin ND-A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/carbidopa Delivered via a Pump System as a Continuous Subcutaneous Infusion in Subjects with Advanced Parkinson's Disease 15

CRONO Twin ND-A Phase III Randomized, Open-Label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-cell Lung Cancer (NSCLC): MYSTIC 15

ND0601 Dermal Patch-Product Status 16

ND0601 Dermal Patch-Product Description 16

ND0611 Dermal Patch-Product Status 17

ND0611 Dermal Patch-Product Description 17

ND0612H Belt Pump-Product Status 18

ND0612H Belt Pump-Product Description 18

ND0612L Patch Pump-Product Status 19

ND0612L Patch Pump-Product Description 19

ND0612L Patch Pump-A Follow-up Comparison Pharmacokinetic Study of ND-0701 (Apomorphine) 20

ND0901-Product Status 21

ND0901-Product Description 21

NeuroDerm Ltd, Key Employees 23

Glossary 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Intec Pharma Ltd

XTL Biopharmaceuticals Ltd

Neurim Pharmaceuticals Ltd

NeuroDerm Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license
Single User License
USD 750 INR 51465
Site License
USD 1,500 INR 69
Corporate User License
USD 2,250 INR 137



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]